Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: A primer for the non-radiologist

Mayo Clinic Proceedings

Volumn 87, Issue 4, 2012, Pages 390-402

  Pasternak, Jeffrey J ^a   Williamson, Eric E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; ANTIHISTAMINIC AGENT; ATROPINE; BICARBONATE; CORTICOSTEROID; DIATRIZOATE; DIMER; DIPHENHYDRAMINE; DOPAMINE; EPHEDRINE; FENOLDOPAM; FUROSEMIDE; GADOLINIUM; HYDROCORTISONE; INFUSION FLUID; INTERLEUKIN 2; IODINATED CONTRAST MEDIUM; IOHEXOL; MANNITOL; MEGLUMINE DIATRIZOATE; METHYLPREDNISOLONE; MONOMER; ONDANSETRON; PREDNISONE; PROCHLORPERAZINE;

ANAPHYLAXIS; ANGIOCARDIOGRAPHY; ANGIONEUROTIC EDEMA; AORTOGRAPHY; ARTERIOGRAPHY; ASTHMA; ATOPY; BRADYCARDIA; BRAIN ANGIOGRAPHY; BRONCHOSPASM; CATHETER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CONTRAST MEDIUM EXTRAVASATION; DELAYED HYPERSENSITIVITY; DIGITAL SUBTRACTION ANGIOGRAPHY; DIURESIS; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; FLUOROSCOPY; HEMODYNAMICS; HUMAN; HYDRATION; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE PAIN; INTRAVASCULAR DRUG ADMINISTRATION; LARYNX EDEMA; LOW DRUG DOSE; LUNG ANGIOGRAPHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; OSMOLARITY; PERIPHERAL ARTERIOGRAPHY; PRACTICE GUIDELINE; PRURITUS; PYELOGRAPHY; RADIODIAGNOSIS; RADIOLOGY; RASH; REVIEW; SHOCK; SIDE EFFECT; SKIN DISEASE; SPINAL ANGIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URTICARIA; VERTEBRAL ANGIOGRAPHY; VISCERAL ARTERIOGRAPHY; VISCOSITY; VOMITING;

EID: 84859847522     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.01.012     Document Type: Review

References (77)

1. Christiansen C. X-ray contrast media: an overview. Toxicology. 2005;209(2):185-187.
2. Dean JA, ed. Lange's Handbook of Chemistry. 14th ed. New York, NY: McGraw Hill; 1992:4.18.
3. Thomsen HS, Morcos SK. Radiographic contrast media. BJU Int. 2000;86(suppl 1):1-10. (Pubitemid 30453633)
4. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology. 1997;204(2):297-312. (Pubitemid 27337471)
5. Kalsch H, Kalsch T, Eggebrecht H, Konorza T, Kahlert P, Erbel R. Gadolinium-based coronary angiography in patients with contraindication for iodinated x-ray contrast medium: a word of caution. J Interv Cardiol. 2008;21(2):167-174. (Pubitemid 351490134)
6. Fleischmann D, Kamaya A. Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am. 2009;47(1):13-26.
7. Justesen P, Downes M, Grynne BH, Lang H, Rasch W, Seim E. Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide. Cardiovasc Intervent Radiol. 1997; 20(4):251-256. (Pubitemid 27297510)
8. Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010; 256(1):32-61.
9. Dawson C, Corry DA, Bowsher WG, Nockler IB, Whitfield HN. Use of image enhancement during lithotripsy. J Endourol. 1996;10(4):335-339. (Pubitemid 26320736)
10. Weininger M, Barraza JM, Kemper CA, Kalafut JF, Costello P, Schoepf UJ. Cardiothoracic CT angiography: current contrast medium delivery strategies. AJR Am J Roentgenol. 2011;196(3): W260-W272.
11. Wang CL, Cohan RH, Ellis JH, Adusumilli S, Dunnick NR. Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69,657 intravenous injections. Radiology. 2007;243(1):80-87. (Pubitemid 46579697)
12. Wienbeck S, Fischbach R, Kloska SP, et al. Prospective study of access site complications of automated contrast injection with peripheral venous access in MDCT. AJR Am J Roentgenol. 2010;195(4):825-829.
13. Schaverien MV, Evison D, McCulley SJ. Management of large volume CT contrast medium extravasation injury: technical refinement and literature review. J Plast Reconstr Aesthet Surg. 2008;61(5):562-565. (Pubitemid 351626728)
14. Ridley LJ. Allergic reactions to oral iodinated contrast agents: reactions to oral contrast. Australas Radiol. 1998;42(2):114- 117.
15. Seymour CW, Pryor JP, Gupta R, Schwab CW. Anaphylactoid reaction to oral contrast for computed tomography. J Trauma. 2004;57(5):1105-1107. (Pubitemid 39579301)
16. Rosati G, Leto di Priolo S, Tirone P. Serious or fatal complications after inadvertent administration of ionic water-soluble contrast media in myelography. Eur J Radiol. 1992;15(2):95- 100.
17. American College of Radiology Manual on Contrast Media. Appendix A. 2010. http://www.acr.org/SecondaryMainMenu Categories/quality-safety/contrast-manual. aspx. Accessed July 2, 2011.
18. Dickinson MC, Kam PC. Intravascular iodinated contrast media and the anaesthetist. Anaesthesia. 2008;63(6):626-634. (Pubitemid 351677331)
19. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175(3):621-628. (Pubitemid 20191915)
20. Hartman GW, Hattery RR, Witten DM, Williamson B Jr. Mortality during excretory urography: Mayo Clinic experience. AJR Am J Roentgenol. 1982;139(5):919-922. (Pubitemid 12003694)
21. Shehadi WH. Death following intravascular administration of contrast media. Acta Radiol Diagn (Stockh). 1985;26(4):457- 461.
22. Kinnison ML, Powe NR, Steinberg EP. Results of randomized controlled trials of low-versus high-osmolality contrast media. Radiology. 1989;170(2):381-389.
23. Beynon HL, Walport MJ, Dawson P. Vascular endothelial injury by intravascular contrast agents. Invest Radiol. 1994;29(suppl 2):S195-S197.
24. Sumimura T, Sendo T, Itoh Y, et al. Calcium-dependent injury of human microvascular endothelial cells induced by a variety of iodinated radiographic contrast media. Invest Radiol. 2003; 38(6):366-374. (Pubitemid 36627254)
25. Oowaki K, Saigusa H, Ojiri H, et al. Relationship between oral food intake and nausea caused by intravenous injection of iodinated contrast material [in Japanese]. Nihon Igaku Hoshasen Gakkai Zasshi. 1994;54(6):476-479.
26. Almen T. The etiology of contrast medium reactions. Invest Radiol. 1994;29(suppl 1):S37-S45. (Pubitemid 24182853)
27. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-480.
28. Simons FE, Ardusso LR, Bilo MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-593.
29. Vervloet D, Durham S. Adverse reactions to drugs. BMJ. 1998;316(7143):1511-1514.
30. Laroche D, Aimone-Gastin I, Dubois F, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology. 1998;209(1):183-190. (Pubitemid 28464665)
31. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115(4):270-276.
32. Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol. 2001;11(7):1267-1275. (Pubitemid 32755608)
33. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987;317(14):845-849. (Pubitemid 17156727)
34. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. AJR Am J Roentgenol. 1994;162(3):523-526.
35. Wolf GL, Mishkin MM, Roux SG, et al. Comparison of the rates of adverse drug reactions: ionic contrast agents, ionic agents combined with steroids, and nonionic agents. Invest Radiol. 1991;26(5):404-410.
36. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1991;87(4):867-872.
37. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis: a statement of the World Allergy Organization. Allergy. 2008;63(8):1061-1070.
38. Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock. JAMA. 1984;251(16): 2118-2122. (Pubitemid 14133508)
39. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol. 2003;3(4):313-318. (Pubitemid 37010889)
40. Loh S, Bagheri S, Katzberg RW, Fung MA, Li CS. Delayed adverse reaction to contrast-enhanced CT: a prospective single- center study comparison to control group without enhancement. Radiology. 2010;255(3):764-771.
41. Savill JS, Barrie R, Ghosh S, Muhlemann M, Dawson P, Pusey CD. Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. Postgrad Med J. 1988;64(751):392-394.
42. Wood BP, Lane AT, Rabinowitz R. Cutaneous reaction to contrast material. Radiology. 1988;169(3):739-740.
43. Sutton AG, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J. 2001;141(4):677- 683.
44. Mikkonen R, Vehmas T, Granlund H, Kivisaari L. Seasonal variation in the occurrence of late adverse skin reactions to iodine-based contrast media. Acta Radiol. 2000;41(4):390-393.
45. Scherer K, Harr T, Bach S, Bircher AJ. The role of iodine in hypersensitivity reactions to radio contrast media. Clin Exp Allergy. 2010;40(3):468-475.
46. Shulman KL, Thompson JA, Benyunes MC, Winter TC, Fefer A. Adverse reactions to intravenous contrast media in patients treated with interleukin-2. J Immunother Emphasis Tumor Immunol. 1993;13(3):208-212. (Pubitemid 23093228)
47. Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media: a European multicenter study. Allergy. 2009;64(2):234- 241.
48. Caimmi S, Benyahia B, Suau D, et al. Clinical value of negative skin tests to iodinated contrast media. Clin Exp Allergy. 2010; 40(5):805-810.
49. Watanabe H, Sueki H, Nakada T, Akiyama M, Iijima M. Multiple fixed drug eruption caused by iomeprol (Iomeron), a nonionic contrast medium. Dermatology. 1999;198(3):291- 294.
50. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc. 2008;83(10):1095-1100.
51. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275(19): 1489-1494. (Pubitemid 26140761)
52. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76(908):513-518. (Pubitemid 37028403)
53. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264. (Pubitemid 34535335)
54. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res. 1992;53(4):317-320.
55. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461- 1471. (Pubitemid 40803495)
56. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239(2):392-397.
57. Rundback JH, Nahl D, Yoo V. Contrast-induced nephropathy. J Vasc Surg. 2011;54(2):575-579.
58. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068-1073. (Pubitemid 35335595)
59. Morcos SK, Thomsen HS, Webb JA; Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol. 1999;9(8):1602-1613.
60. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114(6):1570-1574. (Pubitemid 128487477)
61. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329-336. (Pubitemid 34127411)
62. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328-2334. (Pubitemid 38656299)
63. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3(1):10-18.
64. Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2010;74(4):288-296.
65. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study; Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33(2):403-411. (Pubitemid 29234202)
66. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416-1420. (Pubitemid 24348355)
67. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004;19(7):1803-1807.
68. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15(3):761-769. (Pubitemid 38294807)
69. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(9):874 e9-15.
70. Fishbane S, Durham JH, Marzo K, Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol. 2004;15(2):251-260. (Pubitemid 38140765)
71. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212-218. (Pubitemid 38235157)
72. Weisberg LS, Kurnik PB, Kurnik BR. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail. 1993;15(1):61-68. (Pubitemid 23054064)
73. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv. 2002;55(2):169-173. (Pubitemid 34127374)
74. Teirstein PS, Price MJ, Mathur VS, Madyoon H, Sawhney N, Baim DS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol. 2006;97(7):1076-1081.
75. Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther. 2009;16(1):1-12.
76. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001;111(9):692-698. (Pubitemid 34017520)
77. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast- agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349(14):1333- 1340. (Pubitemid 37186211)